Comparar compuestos
Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.
Peptijournal · Sermorelin vs Tesamorelin · https://peptijournal.com/compare?c=sermorelin,tesamorelin · Impreso
01Protocol
Sermorelin
- Viales
- 5 / 10 mg
- Datos de dosis
- Referencia de laboratorio; no indicado
Tesamorelin
- Viales
- 10 / 20 mg
- Datos de dosis
- Referencia de laboratorio; no indicado
02Quick calculator
Sermorelin
Tesamorelin
03Mechanism of action
Sermorelin
Sermorelin is the first 29 amino acids of GHRH, the shortest fully active fragment. It stimulates pituitary GHRH receptors to release GH.
Tesamorelin
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl modification that improves stability against dipeptidyl peptidase-4 cleavage. It binds GHRH receptors on anterior pituitary somatotrophs, activating Gs/cAMP signaling to stimulate pulsatile endogenous growth hormone release, which in turn raises circulating IGF-1.
04Study endpoints
Sermorelin
- Used intravenously as a diagnostic test for GH deficiency, though a normal response cannot rule out hypothalamic causes.
- In some prepubertal children with idiopathic GH deficiency, height velocity increased significantly over 12 months, with limited data to 36 months.
Tesamorelin
- Reduced visceral adipose tissue (VAT) measured by CT in phase 3 trials in HIV-infected adults with abdominal fat accumulation.
- Increased IGF-1 levels while largely preserving physiological pulsatile GH secretion.
- Reduced hepatic fat fraction in HIV-associated fatty liver studies.
- VAT reductions were not maintained after treatment discontinuation in trial extension phases.
05Safety & regulatory findings
Sermorelin
- Was FDA-approved (Geref) but the branded product was discontinued; it is now mainly compounded or sold for research.
- Listed as prohibited in sport by the World Anti-Doping Agency.
Tesamorelin
- FDA-approved in 2010 (Egrifta) specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.
- Label notes that long-term cardiovascular benefit and safety have not been established, and it is not indicated for weight loss.
- The cited approval does not establish efficacy outside its indication or approve research-market vials.